Riluzole in Patients With Spinocerebellar Ataxia Type 7
Status:
Unknown status
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
Spinocerebellar ataxia type 7 (SCA7) belongs to the dominant forms of inherited cerebellar
ataxias (CA), being one of the rarest form. SCA7 has no therapeutic options, so that the
relentless course, the important visual deficit that accompanies CA, and the possibility of
disease development in childhood are pressing unmet needs. The investigators published
encouraging data on riluzole in inherited CA other than SCA7. These results prompted
off-label use of riluzole in single cases of SCA7 in Italy and United States, suggesting
possible efficacy of the drug in this condition.